Ketamine Trial for Long COVID Symptoms Shows Promise for Fatigue and Brain Fog
A clinical trial is evaluating the efficacy of ketamine in treating Long COVID symptoms, particularly fatigue and cognitive issues.
Phase III
Infectious Disease / Long COVID
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The ongoing clinical trial evaluating ketamine for Long COVID symptoms could significantly alter treatment paradigms in this area, which currently lacks effective options. A successful outcome may lead to new therapeutic protocols and influence future drug development strategies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and participant feedback on symptom improvement and safety profiles post-treatment.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.